跳至主要内容
临床试验/NCT06456554
NCT06456554
招募中
不适用

Acellular Dermal Matrix Investigation in Breast Reconstruction

RTI Surgical11 个研究点 分布在 1 个国家目标入组 467 人2024年11月22日

概览

阶段
不适用
干预措施
no Acellular Dermal Matrix
疾病 / 适应症
Breast Reconstruction
发起方
RTI Surgical
入组人数
467
试验地点
11
主要终点
Health related quality of life
状态
招募中
最后更新
3个月前

概览

简要总结

Prospective, multi-center, dual-arm non-randomized clinical study in females undergoing a two-stage breast reconstruction using a pre-pectoral technique.

注册库
clinicaltrials.gov
开始日期
2024年11月22日
结束日期
2027年12月1日
最后更新
3个月前
研究类型
Interventional
研究设计
Parallel
性别
Female

研究者

发起方
RTI Surgical
责任方
Sponsor

入排标准

入选标准

  • Genetic female
  • Age 22 or older at time of consent
  • Undergoing immediate breast reconstruction
  • 2 stage breast reconstruction using pre pectoral technique
  • Nipple or skin sparing mastectomy
  • Willing and capable of providing informed consent
  • Able to comply with study requirements

排除标准

  • Planned concurrent reconstruction with pedicled flaps or free tissue
  • Pregnant or breast feeding
  • Investigator has determined tissue is unsuitable for two-stage breast reconstruction
  • History of psychological characteristics that may be incompatible with the surgical procedure and the prosthesis
  • Any serious and/or unstable pre-existing medical disorder or other conditions that could interfere with the subject's safety, the informed consent process, or compliance with the study protocol, in the opinion of the investigator
  • Vulnerable subject populations
  • Currently participating in another clinical trial that would have the potential to interfere or conflict with the treatment, follow-up, or objectives of this study
  • Prior history of neoadjuvant radiotherapy to the reconstruction site or chest wall
  • Active abscess or infection in the intended reconstruction site
  • Residual gross tumor at the intended reconstruction site

研究组 & 干预措施

no Acellular Dermal Matrix

Breast reconstruction only with no ADM

Acellular Dermal Matrix

Breast reconstruction with Cortiva Tissue Matrix

干预措施: Acellular Dermal Matrix (Cortiva Tissue Matrix)

结局指标

主要结局

Health related quality of life

时间窗: 12 months

Change from baseline in quality of life as measured by the BREAST-Q Physical Well-Being

Rate of major adverse events

时间窗: 12 months

Surgery-related adverse events requiring rehospitalization or reoperation of the breast under study

次要结局

  • Histopathology assessment(stage 2 procedure)
  • Investigational device related adverse events(3 months, 1 year and 2 years)
  • Change in quality of life(1 year and 2 years)
  • Procedure related adverse events(3 months, 1 year and 2 years)

研究点 (11)

Loading locations...

相似试验